

CANC

Tema Oncology ETF

Analyst Report

CANC is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations.

ESG Themes and Scores

5.34/10

ESG Rate

19.45%

Global Percentile

10.43%

Peer Percentile

Performance Data

	CANC	ETF Database Category Average	Factset Segment Average
1 Month	-3.13%	-6.19%	-4.01%
3 Month	4.60%	-3.39%	-1.31%
YTD Return	2.95%	-4.36%	-2.60%
1 Year Return	41.62%	15.94%	19.58%
3 Year Return	N/A	7.02%	1.49%
5 Year Return	N/A	0.17%	0.00%

Top 5 Holdings

Symbol	Holding	% Assets
RVMD	Revolution Medicines, Inc.	6.12%
AZN	AstraZeneca PLC	4.45%
NOVN	Novartis AG	4.42%
RHHBY	Roche Holding Ltd Sponsored ADR	4.24%
LLY	Eli Lilly and Company	3.99%

Vitals

Issuer	Tema Global Ltd.
Brand	Tema
Structure	ETF
Expense Ratio	0.75%
Inception	Aug 15, 2023
Index Tracked	N/A

ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Growth
Region (General)	Global
Region (Specific)	Broad

FactSet Classifications

Segment	Equity: Global Pharma, Biotech & Life Sciences
Category	Sector
Focus	Health Care
Niche	Pharma, Biotech & Life Sciences
Strategy	Active
Weighting	Proprietary

